SYDNEY, Australia I July 14, 2025 I Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to ...

OSAKA, Japan and CAMBRIDGE, MA, USA I July 14, 2025 I Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two ...

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo ...

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable ...

SAN DIEGO, CA, USA I July 11, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...

AdventHealth Avista, an Orthopedic and Spine Center of Excellence, conducted the first lumbar fusion procedure with PearlMatrix Bone Graft, the first and only ...

ROCKVILLE, MD, USA and SUZHOU, China I July 10, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing ...

BALA CYNWYD, PA, USA I July 08, 2025 I Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...

New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival ...

PALM BEACH GARDENS, FL, USA I July 10, 2025 I Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an ...